Details:
Zerviate (cetirizine hydrochloride) is an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors, it is indicated for treatment of ocular itching associated with allergic conjunctivitis.
Lead Product(s): Cetirizine Dihydrochloride
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: OcuMension Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Europe.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Alimera Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Details:
ZERVIATE is the first and only topical ocular formulation of the antihistamine cetirizine and has been commercialized in the United States since March 2020 by Nicox’s exclusive U.S. licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen (Japan).
Lead Product(s): Cetirizine
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: OcuMension Therapeutics
Deal Size: $19.2 million Upfront Cash: Undisclosed
Deal Type: Agreement July 05, 2021
Details:
Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestone payments.
Lead Product(s): Latanoprostene Bunod
Therapeutic Area: Ophthalmology Product Name: Vyzulta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually after surgery.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Clilon
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Ache Laboratorios Farmaceuticos SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.
Lead Product(s): Latanoprostene Bunod
Therapeutic Area: Ophthalmology Product Name: Vyzulta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.
Lead Product(s): Cetirizine
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 15, 2021